Your browser doesn't support javascript.
loading
Elevation of fatty acid desaturase 2 in esophageal adenocarcinoma increases polyunsaturated lipids and may exacerbate bile acid-induced DNA damage.
Molendijk, Jeffrey; Kolka, Cathryn M; Cairns, Henry; Brosda, Sandra; Mohamed, Ahmed; Shah, Alok K; Brown, Ian; Hodson, Mark P; Hennessy, Thomas; Liu, Guanghao; Stoll, Thomas; Richards, Renee S; Gartside, Michael; Patel, Kalpana; Clemons, Nicholas J; Phillips, Wayne A; Barbour, Andrew; Westerhuis, Johan A; Hill, Michelle M.
Afiliação
  • Molendijk J; The University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, Australia.
  • Kolka CM; Precision and Systems Biomedicine Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia.
  • Cairns H; Precision and Systems Biomedicine Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia.
  • Brosda S; Precision and Systems Biomedicine Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia.
  • Mohamed A; The University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, Australia.
  • Shah AK; The University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, Australia.
  • Brown I; Precision and Systems Biomedicine Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia.
  • Hodson MP; The University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, Australia.
  • Hennessy T; Precision and Systems Biomedicine Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia.
  • Liu G; Envoi Pathology, Herston, Australia.
  • Stoll T; School of Pharmacy, The University of Queensland, Woolloongabba, Australia.
  • Richards RS; The University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, Australia.
  • Gartside M; Agilent Technologies, Mulgrave, Australia.
  • Patel K; Precision and Systems Biomedicine Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia.
  • Clemons NJ; Precision and Systems Biomedicine Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia.
  • Phillips WA; Precision and Systems Biomedicine Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia.
  • Barbour A; The University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, Australia.
  • Westerhuis JA; The University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, Australia.
  • Hill MM; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia.
Clin Transl Med ; 12(5): e810, 2022 05.
Article em En | MEDLINE | ID: mdl-35560527
ABSTRACT

BACKGROUND:

The risk of esophageal adenocarcinoma (EAC) is associated with gastro-esophageal reflux disease (GERD) and obesity. Lipid metabolism-targeted therapies decrease the risk of progressing from Barrett's esophagus (BE) to EAC, but the precise lipid metabolic changes and their roles in genotoxicity during EAC development are yet to be established.

METHODS:

Esophageal biopsies from the normal epithelium (NE), BE, and EAC, were analyzed using concurrent lipidomics and proteomics (n = 30) followed by orthogonal validation on independent samples using RNAseq transcriptomics (n = 22) and immunohistochemistry (IHC, n = 80). The EAC cell line FLO-1 was treated with FADS2 selective inhibitor SC26196, and/or bile acid cocktail, followed by immunofluorescence staining for γH2AX.

RESULTS:

Metabolism-focused Reactome analysis of the proteomics data revealed enrichment of fatty acid metabolism, ketone body metabolism, and biosynthesis of specialized pro-resolving mediators in EAC pathogenesis. Lipidomics revealed progressive alterations (NE-BE-EAC) in glycerophospholipid synthesis with decreasing triglycerides and increasing phosphatidylcholine and phosphatidylethanolamine, and sphingolipid synthesis with decreasing dihydroceramide and increasing ceramides. Furthermore, a progressive increase in lipids with C20 fatty acids and polyunsaturated lipids with ≥4 double bonds were also observed. Integration with transcriptome data identified candidate enzymes for IHC validation Δ4-Desaturase, Sphingolipid 1 (DEGS1) which desaturates dihydroceramide to ceramide, and Δ5 and Δ6-Desaturases (fatty acid desaturases, FADS1 and FADS2), responsible for polyunsaturation. All three enzymes showed significant increases from BE through dysplasia to EAC, but transcript levels of DEGS1 were decreased suggesting post-translational regulation. Finally, the FADS2 selective inhibitor SC26196 significantly reduced polyunsaturated lipids with three and four double bonds and reduced bile acid-induced DNA double-strand breaks in FLO-1 cells in vitro.

CONCLUSIONS:

Integrated multiomics revealed sphingolipid and phospholipid metabolism rewiring during EAC development. FADS2 inhibition and reduction of the high polyunsaturated lipids effectively protected EAC cells from bile acid-induced DNA damage in vitro, potentially through reduced lipid peroxidation.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esôfago de Barrett / Adenocarcinoma Limite: Humans Idioma: En Revista: Clin Transl Med Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esôfago de Barrett / Adenocarcinoma Limite: Humans Idioma: En Revista: Clin Transl Med Ano de publicação: 2022 Tipo de documento: Article